Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other research analysts also recently issued research reports about the stock. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $46.20 on Friday. The stock has a market capitalization of $2.68 billion, a PE ratio of -90.59, a price-to-earnings-growth ratio of 0.99 and a beta of 0.54. The company has a 50 day moving average price of $46.48 and a two-hundred day moving average price of $49.24. Supernus Pharmaceuticals has a 12-month low of $32.53 and a 12-month high of $59.68.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB lifted its holdings in shares of Supernus Pharmaceuticals by 8.9% during the second quarter. Handelsbanken Fonder AB now owns 20,716 shares of the specialty pharmaceutical company’s stock worth $964,000 after buying an additional 1,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 2.0% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 90,213 shares of the specialty pharmaceutical company’s stock valued at $4,196,000 after acquiring an additional 1,759 shares during the period. Empowered Funds LLC bought a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $264,000. Bank of America Corp DE grew its stake in shares of Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after acquiring an additional 193,479 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Supernus Pharmaceuticals by 26.9% in the first quarter. California State Teachers Retirement System now owns 67,686 shares of the specialty pharmaceutical company’s stock worth $3,499,000 after acquiring an additional 14,347 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.